Carisma Therapeutics Inc (CARM) concluded trading on Thursday at a closing price of $0.18, with 6.04 million shares of worth about $1.09 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -82.10% during that period and on May 15, 2025 the price saw a loss of about -7.52%. Currently the company’s common shares owned by public are about 41.79M shares, out of which, 21.12M shares are available for trading.
Stock saw a price change of -17.14% in past 5 days and over the past one month there was a price change of -9.44%. Year-to-date (YTD), CARM shares are showing a performance of -57.40% which decreased to -87.95% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.16 but also hit the highest price of $1.90 during that period. The average intraday trading volume for Carisma Therapeutics Inc shares is 270.25K. The stock is currently trading -13.55% below its 20-day simple moving average (SMA20), while that difference is down -35.03% for SMA50 and it goes to -72.75% lower than SMA200.
Carisma Therapeutics Inc (NASDAQ: CARM) currently have 41.79M outstanding shares and institutions hold larger chunk of about 11.50% of that.
The stock has a current market capitalization of $7.45M and its 3Y-monthly beta is at 1.70. It has posted earnings per share of -$1.22 in the same period. It has Quick Ratio of 1.34. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CARM, volatility over the week remained 18.43% while standing at 13.77% over the month.
Stock’s fiscal year EPS is expected to rise by 52.71% while it is estimated to increase by 1.64% in next year. EPS is likely to shrink at an annualized rate of 27.09% for next 5-years, compared to annual growth of 42.71% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on December 12, 2024 offering a Neutral rating for the stock and assigned a target price range of between $10 and $1 to it. On April 11, 2024, BTIG Research Initiated their recommendations, while on October 03, 2023, CapitalOne Initiated their ratings for the stock with a price target of $10. Stock get an Outperform rating from Evercore ISI on July 06, 2023.
